What is Saranas?
Saranas operates at the intersection of medical technology and patient safety, specializing in the development of the Early Bird Bleed Monitoring System. This patented platform is engineered to provide real-time detection and monitoring of internal bleeding complications, a common and costly challenge in vascular access procedures. By enabling physicians to identify and mitigate bleeding events immediately, the company's technology serves a dual purpose: improving clinical outcomes for patients and significantly reducing the economic burden on healthcare systems. As a privately held entity, Saranas has established itself as a key player in the medical device landscape, focusing on high-acuity care environments where precision and early intervention are paramount to success.
How much funding has Saranas raised?
Saranas has raised a total of $28.1M across 7 funding rounds:
Angel/Seed
$1.2M
Unspecified
$2.4M
Series A
$3.5M
Private Equity
$1.4M
Series B
$4M
Series C
$2.8M
Series B
$12.8M
Angel/Seed (2014): $1.2M, investors not publicly disclosed
Unspecified (2015): $2.4M, investors not publicly disclosed
Series A (2016): $3.5M supported by Houston Angel Network
Private Equity (2016): $1.4M, investors not publicly disclosed
Series B (2017): $4M, investors not publicly disclosed
Series C (2018): $2.8M, investors not publicly disclosed
Series B (2021): $12.8M led by Baird Capital and S3 Ventures
Key Investors in Saranas
Baird Capital
Baird Capital is a global private equity and venture capital firm that partners with founder-led B2B tech and services companies, providing deep institutional knowledge and operational support to foster long-term growth.
S3 Ventures
S3 Ventures is the largest venture capital firm focused on Texas, specializing in healthcare technology and business software with a commitment to supporting visionary founders through flexible, patient capital.
Houston Angel Network
The Houston Angel Network is a prominent group of accredited investors dedicated to fueling the growth of early-stage startups in the Texas region through strategic mentorship and initial capital deployment.
What's next for Saranas?
With the recent influx of capital, Saranas is poised to enter a new phase of operational scaling and market penetration. The company's roadmap likely involves broadening the clinical adoption of the Early Bird system across major hospital networks and investing in further research and development to enhance its diagnostic capabilities. As the firm transitions from its earlier development stages into a more mature commercial entity, the focus will shift toward establishing long-term partnerships with healthcare providers and demonstrating the sustained value proposition of its technology in diverse clinical settings. This strategic trajectory positions Saranas to become a standard-bearer for safety in vascular procedures, potentially attracting further interest from institutional investors focused on high-impact healthcare innovation.
See full Saranas company page
